Cardiac Effects of Renin-Angiotensin System Inhibitors in Nonproteinuric CKD.
Rachel ShulmanWei YangDebbie L CohenPeter P ReeseJordana B Cohennull nullPublished in: Hypertension (Dallas, Tex. : 1979) (2024)
Among individuals with nonproteinuric CKD, after accounting for time-updated use, RASIs are associated with fewer cardiovascular events and a lower mortality risk compared with other antihypertensive medications. Patients with nonproteinuric CKD may benefit from prioritizing RASIs for hypertension management.